Report : Europe Anti-Infective Agents Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Anti-Viral, Anti-Bacterial, Anti-Fungal, and Others), Range (Narrow Spectrum and Broad Spectrum), Route of Administration (IV, Oral, Topical, and Others), Indication (HIV, Tuberculosis, Respiratory Infection, Pneumonia, and Others), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Specialty Pharmacies, E-Commerce, and Others)       

At 3.0% CAGR, the Europe Anti-Infective Agents Market is speculated to be worth US$ 49,527.90 Million by 2028, says Business Market Insights

According to Business Market Insights’ research, the Europe anti-infective agents market was valued at US$ 45,331.11 million in 2022 and is expected to reach US$ 55,179.54 million by 2028, registering an annual growth rate of 3.3% from 2022 to 2028. Increasing prevalence of chronic diseases and surging government support for research activities including clinical trials are the critical factors attributed to the market expansion.

Chronic diseases are conditions that develop over an extended period due to a combination of genetic, physiological, environmental, and behavioral variables. The four primary categories of NCD are diabetes, cancer, chronic respiratory diseases (such as chronic obstructive pulmonary disease and asthma), and cardiovascular disorders (including heart attacks and stroke). The rising prevalence of anti-infective resistance, which has now become a public health issue, poses a hazard to human health. Antibacterial, antiviral, antifungal, and antiparasitic drugs are examples of anti-infectives, which work to prevent or treat infections. Antibiotics are chemically derived antimicrobial medications that cure and prevent bacterial illnesses by eradicating or preventing their growth. Azithromycin, clarithromycin, and erythromycin are examples of macrolides, which have historically been the main antibiotic classes, studied for their potential role in the secondary prevention of coronary heart diseases.  

The study of cancer genesis has advanced to the cellular and molecular levels due to the rapid growth of contemporary science and technology, particularly biomedicine, in the 20th century. Modern cell biology describes malignancies as a group of biological illnesses distinguished by aberrant cell proliferation. Since every cancer begins in a single cell, cancers are also diseases that include alterations in the structure and function of genetic material. Since cancer cells proliferate, they pass on their malignant activity to their offspring (DNA). In the meantime, cancer formation and incidence are also promoted by the invasive growth and spread of cancer cells. One of the most significant classes of antibiotics with their unique inhibitory effects on malignancies is the anti-cancer class. The antiproliferative, pro-apoptotic, and anti-epithelial-mesenchymal-transition (EMT) properties of several antibiotics have been employed in the treatment of cancer. Thus, the increasing prevalence of chronic diseases is driving the Europe anti-infective agents market.

On the contrary, emergence of anti-infective drugs resistance and their various side effects hurdles the growth of Europe anti-infective agents market.

Based on type, the market is segmented into anti-bacterial, anti-viral, anti-fungal, and others. The anti-viral segment held the largest market share of 47.2% in 2022 with a revenue of US$ 19,546.87 million. Further, it is going to reach US$ 23,105.57 million by 2028 at  decent CAGR of 2.8% during the forecasted period.

Based on range, the anti-infective agents market sphere is bifurcated into broad spectrum and narrow spectrum. The former held 62.9% market share in 2022, amassing US$ 26,067.32 million. It is projected to garner US$ 30,800.55 million by 2028 to expand at 2.8% CAGR during 2022–2028.

Based on route of administration, the market is segmented into topical, oral, IV, and others. With 51.3% share IV segment dominated the market in 2022. It accrued US$ 21,254.42 million in 2022 and is estimated to reach by US$ 25,118.48 million by 2028 at a CAGR of 2.8% during 2022-2028.

Based on indication, the market is segmented into HIV, tuberculosis, respiratory infection, pneumonia, and others. The others segment held the largest market share of 45.1% in 2022 with a revenue of US$ 18,707.76 million. Further, it is going to reach US$ 22,699.02 million by 2028 at  decent CAGR of 3.3% during the forecasted period. 

Based on distribution channel, the market is segmented into hospital pharmacies, specialty pharmacies, e-commerce, and others. With 45.0% share of the domain, the hospital pharmacies segment dominated the market in 2022. It accrued US$ 18,669.36 million in 2022 and is estimated to generate US$ 22,424.47 million by 2028 to grow at a CAGR of 3.1% over the forecast period.

Our country analysis states that Germany captured 22.3% market share in 2022. It was assessed at US$ 9,249.99 million in 2022 and is likely to hit US$ 11,169.68 million by 2028, exhibiting a CAGR of 3.2% during the forecast period.

Key players dominating the Europe anti-infective agents market are Abbott; Allergan Plc.; Astellas Pharma Inc.; Bayer AG; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; GlaxoSmithKline plc.; Merck & Co., Inc.; and Novartis AG among others.

Few of the recent key developments among the top market players are listed below:

  • In April 2021, Abbott launched adult vaccination program for flu, typhoid, and more vaccines to safeguard people's health. The program aimed to create awareness regarding immunization in adult populations.
  • In January 2021, Merck confirmed an agreement with UNICEF to establish the world’s first global Ebola vaccine stockpile with ERVEBO® (Ebola Zaire Vaccine, Live). ERVEBO is a vaccine indicated for the prevention of disease caused by Zaire ebolavirus in individuals 18 years of age and older. 

Contact Us
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email Id:

Download Free PDF Brochure